Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models is delighted to be attending and presenting at a series of investor events from the 9th to 11th July 2020.
Cathal Friel, Open Orphan’s Chief Executive Officer, will be in attendance for all of the events and will be presenting to update existing and potential investors on the Company’s business plans for 2020-2021.
No new material information will be disclosed at any event.
A full schedule of the upcoming events is as follows:
|
Event |
Date/Time |
Location |
|
Hardman & Co Investor Forum Webinar |
July 9th 2020 / 15:00 – 16:30 |
Virtual Event, further information and registration here: Link |
|
Proactive Investors One2One Investor Forum |
July 9th 2020 / 18:00 – 20:00 |
Virtual Event, further information and registration here: Link |
|
Mello Virtual – Investing in the New World |
July 11th 2020 / 9:00 – 17:00 |
Virtual Event, further information and registration here: Link |
For further information please contact
|
Open Orphan plc |
+353 (0)1 644 0007 |
|
Cathal Friel, Executive Chairman |
|
|
Arden Partners plc (Nominated Adviser and Joint Broker) |
+44 (0)20 7614 5900 |
|
John Llewellyn-Lloyd / Benjamin Cryer / Dan Gee-Summons |
|
|
finnCap plc (Joint Broker) |
+44 (0) 20 7220 500 |
|
Geoff Nash / James Thompson/ Richard Chambers |
|
|
Davy (Euronext Growth Adviser and Joint Broker) |
+353 (0)1 679 6363 |
|
Anthony Farrell |
|
|
Camarco (Financial PR) |
+44 (0)20 3757 4980 |
|
Tom Huddart / Hugo Liddy |